Clinical Trial Update: Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Lantus (insulin glargine) and Apidra (insulin glulisine) for Type 1 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Apidra (insulin glulisine)
• Lantus (insulin glargine)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus, Type 1 | Phase 4 | Status: COMPLETED